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follow up period is 14 months. Conclusion: Our initial experience
shows that allogeneic stem cell transplantation is an effective treat-
ment option in patients of chronic myeloid leukaemia in chronic
phase, who are less than 50 years of age and have HLA matched
sibling donor. This is in line with experience from other centers.
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PROGNOSTIC PROGENITOR PROFILING IN CHRONIC MYELOMONO-
CYTIC LEUKEMIA
Jamieson, C.H.M.1; Li, K.1; Gotlib, J.1; Coutre, S.E.1; Lagasse, E.2;
Weissman, I.L.1 1. Stanford University School of Medicine, Stanford,
CA; 2. University of Pittsburgh, Pittsburgh, PA.
Chronic myelomonocytic leukemia (CMML) is a unique myelo-
proliferative disease characterized by marrow dysplasia and an
increase in monocytes. The median survival of patients with
CMML is short, in part, because CMML is frequently resistant to
therapy. A better understanding of the basic biology of CMML
progenitors is needed in order to reduce regimen related toxicity
and provide more effective CMML targeted therapies. To this end,
a mouse transgenic model of CMML was created in which human
bcl-2 overexpression was targeted to the myeloid lineage by the
myeloid promoter hMRP8. Transgenic hMRP8-bcl2 mice devel-
oped a myeloproliferative disorder characterized by a monocytosis
in all hematopoietic tissues and splenomegaly. Myeloid progenitor
analysis of hMRP8-bcl-2 bone marrow revealed a marked ex-
pansion of human bcl-2 expressing granulocyte-macrophage
progenitors compared with control mice. In order to see if
this correlated with human CMML, we used FACS analysis
and recently identiﬁed phenotypic markers to identify pheno-
typic and functional differences between normal and CMML
bone marrow hematopoietic stem cells and myeloid pro-
genitors. CMML marrow was typiﬁed by a reduction in
CD34CD38CD90Lin hematopoietic stem cells and an ex-
pansion of CD34CD38CD90Flk2Lin cells relative to nor-
mal bone marrow. In addition, there was a two-fold expansion in
common myeloid progenitors (CMPs) and a corresponding de-
crease in megakaryocyte-erythroid progenitors (MEPs) suggesting
that there was a skew in differentiation toward the myeloid lineage.
In contrast to normal bone marrow derived CMPs, CMML CMPs
gave rise to myeloid but not erythroid colonies. Moreover, real
time quantitative RT-PCR analysis of highly puriﬁed FACS-sorted
CMML CMPs demonstrated increased expression of two key reg-
ulators of myelomonocytic differentiation, PU.1 and c-jun, com-
pared with normal bone marrow. A more detailed understanding of
the basic biology of CMML progenitors and the genes that work in
concert to expand them may aid in identifying novel molecular
targets for CMML.
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POST-REMISSION THERAPY OF ACUTE MYELOID LEUKEMIA IN FIRST
REMISSION
Kim, S.T.; Kim, K.; Lee, S.H.; Kim, W.S.; Jung, C.W.; Lee, M.H.;
Park, K. Hematology-Oncology, Samsung Medical Center, Sungkyunk-
wan University, Seoul, Korea.
Background: At AML in ﬁrst remission, treatment-modality
depends on patient’s prognostic factor and donor availability. Ac-
cording to the risk group of AML, post remission therapy has not
established. We analyzed the effect of post-remission therapy of
AML in ﬁrst remission, allogeneic, autologous HSCT and inten-
sive chemotherapy. Method: According to the post-remission
therapy, we retrospectively evaluated the prognostic factor, the
event-free survival (EFS) and the overall survival (OS) of 122
patients with AML in ﬁrst remission from 1995 to 2004. All
patients received standard induction therapy. After complete re-
mission had been achieved, consolidation therapy was started.
According to patients’ clinical status and donor availability, pa-
tients were offered the different treatment-modalities, allogeneic,
autologous HSCT or intensive chemotherapy. Result: Twenty-
ﬁve patients received allogeneic HSCT, 36 patients autologous
HSCT and 61 patients intensive chemotherapy. Median age was 33
years in allogeneic HSCT group, 38 years in autologous HSCT
group, and 46 years in intensive chemotherapy group. The 5-year
EFS were 72% in allogeneic HSCT group, 57% in the autologous
HSCT group and 50% in chemotherapy group (p0.049). When
comparing between treatment groups, there was no difference in
EFS. The 5-year OS rates were 80% in allogeneic HSCT group,
60% in autologous HSCT group and 53% in chemotherapy group
(p0.02). There was a signiﬁcant difference in OS only between
allogeneic HSCT group and chemotherapy group (p0.04). There
was an advantage in terms of EFS (p0.04) and OS (p0.03) with
HSCT as compared intensive chemotherapy. The EFS and OS of
allogeneic HSCT as compared with autologous HSCT has not
difference. There was a signiﬁcant beneﬁt for EFS and OS with
HSCT group when compared to those in intensive chemotherapy
group in the high risk group of AML patients (p
0.05). In the
intermediate and low risk group of AML, there was no signiﬁcant
difference in OS with HSCT as compared to the intensive chemo-
therapy, but a signiﬁcant beneﬁt for EFS of HSCT as compared
with the intensive chemotherapy (p
0.05). Conclusion: The
treatment of high risk-AML in ﬁrst remission with either alloge-
neic or autologous hematopoietic stem cell transplantation pro-
longs EFS and OS as compared with intensive chemotherapy. In
the intermediate or low risk-AML, there was a signiﬁcant beneﬁt
for only EFS with HSCT compared as intensive chemotherapy.
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ALLOGENEIC STEM-CELL TRANSPLANTATION IN PATIENTS WITH AML
AND MDS USING MYELOABLATIVE VERSUS REDUCED-INTENSITY
DOSES OF INTRAVENOUS BUSULFAN (BUSULFEX): THE ROLE OF DOSE
INTENSITY
Shimoni, A.; Yeshurun, M.; Hardan, I.; Avigdor, A.; Shem-Tove, N.;
Ben-Bassat, I.; Nagler, A. Chaim Sheba Medical Center, Tel-Hashomer,
Israel.
Allogeneic stem cell transplantation (SCT) is a potentially cura-
tive approach in patients (pts) with AML and MDS. Intravenous
busulfan (Busulfex, ivBu) reduces treatment-related mortality
(TRM) and improves outcome after standard ablative condition-
ing. Reduced-intensity regimens allow SCT in pts not eligible for
standard conditioning. It is not yet well established what are the
dose intensities of ivBu predicting of better outcome in different
settings. 91 pts were included in this analysis; median age 50 years
(range, 18–70). 77 had AML (33 secondary) and 14 had MDS. The
donors were HLA-matched siblings (n45), 1-Ag mismatched
relatives (n6) or matched-unrelated (n40). 42 pts were in ﬁrst
or second remission at SCT, or untreated with 
10% marrow
blasts; 49 were chemo-refractory or with 10% marrow blasts
(active disease). 43 pts had ablative conditioning with ivBu, 12.8
mg/kg (Bu16) and cyclophosphamide (Cy). 48 pts considered not
eligible for ablative therapy were given ﬂudarabine (Flu) and esca-
lated doses of ivBu, 6.4–12.8 mg/kg, (Bu8–16). With a median
follow-up of 14 months, the 2-year overall (OS) of all pts was 48%
(95 CI, 36–61). The cumulative incidence of TRM and relapse
were 15% and 39%, respectively. The most important predictive
factor for OS in multivariant analysis was active disease at SCT
(HR 3.7, p0.001). Age, gender, secondary AML/MDS, donor
type and regimen used were not signiﬁcant. There was no differ-
ence in OS between pts given different doses of ivBu. The OS of
pts given Bu16 (with Cy or Flu) was 49%, compared with 51% in
pts given Flu and Bu8–12. Pts given Bu16 had higher risk of TRM
(19% vs 7%) and lower relapse rate (34% vs 46%), not reaching
statistical signiﬁcance. However, ivBu dose had a signiﬁcant inﬂu-
ence in pts with active disease. OS, TRM and relapse rates were
45%, 22%, and 34% in pts given Bu16 compared with 0%
(p0.05), 18% (pNS), and 82% (p0.04) after Bu8–12, respec-
tively. In conclusion, ivBu containing regimens are well tolerated
with relatively low TRM rates. Dose intensity is not predictive of
outcome in chemo-sensitive disease. However, pts with active
disease could only be salvaged if given ablative doses of ivBu. Pts
considered not eligible for ablative conditioning tolerated Flu and
ablative doses of ivBu relatively well, and could be salvaged with
this regimen even when treated for active disease. Randomized
studies will be needed to further determine the best dose-intensity
in each setting.
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